சுருக்கம்

The role of spironolactone in correction of hormonal disturbance in acne patients

Eman Talat Eleskafy, Mohamed Khalafallla

Introduction: Acne vulgaris is a common chronic skin disease involving blockage and/or inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). Acne can present as non-inflammatory lesions, inflammatory lesions, or a mixture of both, affecting mostly the face but also the back and chest. Polycystic ovary syndrome is the most common cause of hyperandrogenism in women. Spironolactone is an antagonist for mineralocorticoid receptors and used for treatment of hypertension, congestive heart failure, nephrotic syndrome. I t causes decrease of androgen production which lead to decrease sebum so use in the treatment of acne.
Aim of the study: We evaluated the efficacy of spironolactone therapy in women with acne and improvement of hormonal changes.
Patients and Methods: This is a retrospective study done in our hospital between January to December 2022 on 200 patients diagnosed by dermatologist as acne vulgaris. All diagnosed cases were referred to gyncological clinic to evaluate hormones as follicle-stimulating hormone, serum levels of testosterone, dehydroepiandrosterone sulphate, luteinizing hormone, prolactin, and blood sugar, insulin on the second or third day of the cycle. Spironolactone 100 mg was given once daily for all patients for 12 weeks. Follow up was done at weeks 4and 8. Hormonal profile was repeated at Week 12.
Conclusion: Spironolactone reduces hyperandrogenic state with significant improvement of hormonal disturbance in acne patient.